Our mission is to enable food producers to improve their sustainability and profitability.
We develop products and solutions in genetics, health and nutrition that improve performance, animal health and welfare, and reduce environmental impact across the production cycle. Our aim is to be aquaculture’s leading supplier of solutions in genetics, health and specialist nutrition.
Benchmark Q1 Results Presentation 2021
Benchmark’s Advanced Nutrition produces and sells live feed (Artemia), specialist diets, and preventative health products such as probiotics. Advanced Nutrition’s portfolio of products help early stage shrimp and fish develop to their full potential by improving nutrition and increasing resilience to disease challenges.
Products are manufactured in Thailand and the USA and are sold to customers directly and through a global network of distributors.
Benchmark Genetics is one of the world’s leading producers of salmon eggs. Benchmark’s salmon eggs carry specialist genetic traits including resistance to some of the most prevalent diseases. We also produce broodstock and fry for shrimp and tilapia, which carry desirable genetic traits such as growth, quality and disease resistance.
Benchmark’s breeding facilities are located in major aquaculture production markets including Norway, Chile, Iceland, Colombia and the USA.
Benchmark Health manufactures and sells sea lice treatments.
The Group has a pipeline of products in development focussed on addressing some of the industry’s largest unmet needs, including a new sea lice treatment and a portfolio of preventative vaccines for salmon.
- Grow in established markets from existing capacity and through partnerships
- Commercial delivery of pipeline products
- Focused investment in markets that leverage Group platform
- Position Benchmark in areas of future growth
|May 2020||Publication of Interim results|
|August 2020||Q3 update|
|November 2020||Q4 update|
|December 2020||Publication of year end results|
FY2020 Financial Highlights
|Revenue from continuing operations||105.6||124.0|
|Loss before tax from continuing operations||(22.6)||(58.5)|
|Loss from continuing operations||(22.8)||(59.1)|
|Loss - total incl. discontinued operations||(31.9)||(83.1)|
|Basic loss per share (p)||(5.26)||(15.03)|
|Adjusted EBITDA2 from continuing operations||14.5||21.3|
|Adjusted operating profit from continuing operations||7.9||16.3|
|EBITDA1 from continuing operations||12.4||20.8|
(2) Adjusted EBITDA is EBITDA1, before exceptional items and acquisition related expenditure.
(3) Net debt is cash and cash equivalents less loans and borrowings. Net debt includes £9.6m (2019: £nil) relating to lease obligations which are now held on balance sheet following the adoption of IFRS 16.